Premium
Expression of PDGFR‐ β and Kit in canine anal sac apocrine gland adenocarcinoma using tissue immunohistochemistry
Author(s) -
Brown R. J.,
Newman S. J.,
Durtschi D. C.,
LeBlanc A. K.
Publication year - 2012
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/j.1476-5829.2011.00286.x
Subject(s) - immunohistochemistry , receptor tyrosine kinase , pathology , apocrine , malignancy , adenocarcinoma , platelet derived growth factor receptor , biology , angiogenesis , receptor , cancer research , medicine , growth factor , cancer
Canine anal sac apocrine gland adenocarcinoma (ASAGAC) is an uncommon but highly invasive and metastatic malignancy. Toceranib phosphate (Palladia) is a receptor tyrosine kinase (RTK) inhibitor that targets several members of the split kinase RTK family. These membrane receptors are important for cell cycling, apoptosis and angiogenesis, all of which can contribute to carcinogenesis. The objective of this study was to evaluate archived, paraffin‐embedded canine ASAGAC and normal canine anal sacs for immunohistochemical detection of Kit and platelet‐derived growth factor receptor beta (PDGFR‐ β ). Two of 77 neoplasms (2.6%) expressed Kit. Fifteen of the neoplasms (19.5%) were positive for PDGFR‐ β expression. None of the normal canine anal sac epithelium expressed Kit or PDGFR‐ β . Because of these results, further investigation should be considered to determine the role of RTKs in the clinical course and treatment of canine ASAGAC.